Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
9 auth.
N. Bansal,
M. J. Adams,
Sarju Ganatra,
S. Colan,
S. Aggarwal,
R. Steiner,
...
S. Amdani,
Emma R. Lipshultz,
S. Lipshultz
|
7 |
2019 |
7
2019
|
Doxorubicin cardiotoxicity and target cells: a broader perspective
10 auth.
A. De Angelis,
K. Urbanek,
D. Cappetta,
E. Piegari,
L. Ciuffreda,
Alessia Rivellino,
...
R. Russo,
G. Esposito,
F. Rossi,
L. Berrino
|
6 |
2016 |
6
2016
|
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
16 auth.
Sarju Ganatra,
A. Nohria,
Sachin P. Shah,
J. Groarke,
Ajay K. Sharma,
D. Venesy,
R. Patten,
K. Gunturu,
C. Zarwan,
T. Neilan,
...
A. Barac,
S. Hayek,
S. Dani,
S. Solanki,
Syed S Mahmood,
S. Lipshultz
|
6 |
2019 |
6
2019
|
5-FU induced cardiotoxicity: case series and review of the literature
C. Yuan,
Hiral D. Parekh,
C. Allegra,
T. George,
J. Starr
|
5 |
2019 |
5
2019
|
Takotsubo cardiomyopathy in cancer patients
A. Desai,
A. Noor,
S. Joshi,
Agnes S. Kim
|
5 |
2019 |
5
2019
|
Etiology and management of hypertension in patients with cancer
T. Mohammed,
Meghana Singh,
J. Tiu,
Agnes S. Kim
|
5 |
2021 |
5
2021
|
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
O. Pasvolsky,
A. Leader,
Z. Iakobishvili,
Y. Wasserstrum,
R. Kornowski,
P. Raanani
|
5 |
2015 |
5
2015
|
Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic
S. Barros-Gomes,
J. Herrmann,
S. Mulvagh,
A. Lerman,
G. Lin,
H. Villarraga
|
5 |
2016 |
5
2016
|
Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures
A. Yu,
L. Jones
|
5 |
2016 |
5
2016
|
A new classification of cardio-oncology syndromes
14 auth.
R. D. de Boer,
J. Aboumsallem,
V. Bračun,
D. Leedy,
R. Cheng,
Sahishnu Patel,
D. Rayan,
Svetlana Zaharova,
J. Rymer,
J. Kwan,
...
Joshua E Levenson,
C. Ronco,
P. Thavendiranathan,
Sherry‐Ann Brown
|
5 |
2021 |
5
2021
|
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
V. Gregorietti,
T. Fernández,
D. Costa,
Elías Ortega Chahla,
A. Daniele
|
5 |
2020 |
5
2020
|
